Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Case report

A case report of septic shock syndrome caused by S. pneumoniae in an immunocompromised patient despite of vaccination

Authors: Josef Singer, Christoph Testori, Peter Schellongowski, Ammon Handisurya, Catharina Müller, Eva-Maria Reitter, Wolfgang Graninger, Paul Knöbl, Thomas Staudinger, Stefan Winkler, Florian Thalhammer

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background and case presentation

We report a case of septic shock syndrome caused by Streptococcus pneumoniae in a patient who had undergone splenectomy due to an autoimmune lymphoproliferative syndrome (ALPS), which is characterized as a dysfunction of immunoregulation. Although the patient was vaccinated with a conjugated polysaccharide vaccine after the splenectomy, he was still susceptible to S. pneumoniae infection, because the isolated serovar (24F), a serovar long thought to be apathogenic, is not covered by any vaccine currently approved, neither a conjugated nor an unconjugated polysaccharide one.

Conclusions

This case demonstrates that, due to presence of different serovars, also infections with bacteria against which patients are vaccinated have to be considered as differential diagnosis. Although vaccine development has extended the coverage of S. pneumoniae from 7 to 23 serovars within recent years, there is still demand for novel vaccines which can provide broader protection also against so-thought “apathogenic” strains, especially for groups at high risk.
Literature
1.
go back to reference Krone CL, van de Groep K, Trzcinski K, Sanders EA, Bogaert D. Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions. Lancet Respir med. 2014;2(2):141–53.CrossRefPubMed Krone CL, van de Groep K, Trzcinski K, Sanders EA, Bogaert D. Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions. Lancet Respir med. 2014;2(2):141–53.CrossRefPubMed
2.
go back to reference Benninger MS, Manz R. The impact of vaccination on rhinosinusitis and otitis media. Curr Allergy Asthma rep. 2010;10(6):411–8.CrossRefPubMed Benninger MS, Manz R. The impact of vaccination on rhinosinusitis and otitis media. Curr Allergy Asthma rep. 2010;10(6):411–8.CrossRefPubMed
4.
go back to reference Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean med Sci. 2013;28(1):4–15.CrossRefPubMedPubMedCentral Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean med Sci. 2013;28(1):4–15.CrossRefPubMedPubMedCentral
5.
go back to reference Nau R, Djukic M, Spreer A, Eiffert H. Bacterial meningitis: new therapeutic approaches. Expert rev Anti-Infect Ther. 2013;11(10):1079–95.CrossRefPubMed Nau R, Djukic M, Spreer A, Eiffert H. Bacterial meningitis: new therapeutic approaches. Expert rev Anti-Infect Ther. 2013;11(10):1079–95.CrossRefPubMed
6.
go back to reference Ahl J, Littorin N, Forsgren A, Odenholt I, Resman F, Riesbeck K. High incidence of septic shock caused by Streptococcus Pneumoniae serotype 3--a retrospective epidemiological study. BMC Infect dis. 2013;13:492.CrossRefPubMedPubMedCentral Ahl J, Littorin N, Forsgren A, Odenholt I, Resman F, Riesbeck K. High incidence of septic shock caused by Streptococcus Pneumoniae serotype 3--a retrospective epidemiological study. BMC Infect dis. 2013;13:492.CrossRefPubMedPubMedCentral
7.
go back to reference Fedson DS, Nicolas-Spony L, Klemets P, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert rev Vaccines. 2011;10(8):1143–67.CrossRefPubMed Fedson DS, Nicolas-Spony L, Klemets P, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert rev Vaccines. 2011;10(8):1143–67.CrossRefPubMed
9.
go back to reference Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect dis. 2000;30(1):100–21.CrossRefPubMed Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect dis. 2000;30(1):100–21.CrossRefPubMed
10.
go back to reference Feldman C, Anderson R. Review: current and new generation pneumococcal vaccines. J Inf Secur. 2014;69(4):309–25. Feldman C, Anderson R. Review: current and new generation pneumococcal vaccines. J Inf Secur. 2014;69(4):309–25.
11.
go back to reference Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly rep. 2014;63(37):822–5.PubMed Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly rep. 2014;63(37):822–5.PubMed
12.
go back to reference Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101(4 Pt 1):604–11.CrossRefPubMed Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101(4 Pt 1):604–11.CrossRefPubMed
13.
go back to reference Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs. 2009;11(5):349–57.CrossRefPubMed Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs. 2009;11(5):349–57.CrossRefPubMed
14.
go back to reference Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13(R)]. Drugs. 2010;70(15):1973–86.CrossRefPubMed Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13(R)]. Drugs. 2010;70(15):1973–86.CrossRefPubMed
15.
go back to reference Bogaert D, De Groot R, Hermans PW. Streptococcus Pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect dis. 2004;4(3):144–54.CrossRefPubMed Bogaert D, De Groot R, Hermans PW. Streptococcus Pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect dis. 2004;4(3):144–54.CrossRefPubMed
19.
go back to reference Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect dis. 2000;30(1):122–40.CrossRefPubMed Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect dis. 2000;30(1):122–40.CrossRefPubMed
20.
go back to reference Alari A, Chaussade H, Domenech De Celles M, et al. Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis. BMC Med. 2016;14(1):211.CrossRefPubMedPubMedCentral Alari A, Chaussade H, Domenech De Celles M, et al. Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis. BMC Med. 2016;14(1):211.CrossRefPubMedPubMedCentral
21.
go back to reference Rao VK. Approaches to managing autoimmune Cytopenias in novel immunological disorders with genetic underpinnings like autoimmune Lymphoproliferative syndrome. Front Pediatr. 2015;3:65.CrossRefPubMedPubMedCentral Rao VK. Approaches to managing autoimmune Cytopenias in novel immunological disorders with genetic underpinnings like autoimmune Lymphoproliferative syndrome. Front Pediatr. 2015;3:65.CrossRefPubMedPubMedCentral
22.
go back to reference Price S, Shaw PA, Seitz A, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014;123(13):1989–99.CrossRefPubMedPubMedCentral Price S, Shaw PA, Seitz A, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014;123(13):1989–99.CrossRefPubMedPubMedCentral
24.
go back to reference Shah S, Wu E, Rao VK, Tarrant TK. Autoimmune lymphoproliferative syndrome: an update and review of the literature. Curr Allergy Asthma rep. 2014;14(9):462.CrossRefPubMedPubMedCentral Shah S, Wu E, Rao VK, Tarrant TK. Autoimmune lymphoproliferative syndrome: an update and review of the literature. Curr Allergy Asthma rep. 2014;14(9):462.CrossRefPubMedPubMedCentral
25.
go back to reference Leone G, Pizzigallo E. Bacterial infections following Splenectomy for malignant and nonmalignant hematologic diseases. Mediterr J Hematol Infect dis. 2015;7(1):e2015057.CrossRefPubMedPubMedCentral Leone G, Pizzigallo E. Bacterial infections following Splenectomy for malignant and nonmalignant hematologic diseases. Mediterr J Hematol Infect dis. 2015;7(1):e2015057.CrossRefPubMedPubMedCentral
27.
go back to reference Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr. 1995;126(4):646–52.CrossRefPubMed Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr. 1995;126(4):646–52.CrossRefPubMed
28.
go back to reference Knoebl PN. Human protein C concentrates for replacement therapy in congenital and acquired protein C deficiency. Drugs Today (Barc). 2008;44(6):429–41.CrossRef Knoebl PN. Human protein C concentrates for replacement therapy in congenital and acquired protein C deficiency. Drugs Today (Barc). 2008;44(6):429–41.CrossRef
29.
go back to reference Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79(3):918–25.CrossRefPubMedPubMedCentral Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79(3):918–25.CrossRefPubMedPubMedCentral
Metadata
Title
A case report of septic shock syndrome caused by S. pneumoniae in an immunocompromised patient despite of vaccination
Authors
Josef Singer
Christoph Testori
Peter Schellongowski
Ammon Handisurya
Catharina Müller
Eva-Maria Reitter
Wolfgang Graninger
Paul Knöbl
Thomas Staudinger
Stefan Winkler
Florian Thalhammer
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2481-y

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue